Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Recruiting · NCT06561347 · Registry updated 2026-09-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-09-01 | NCT06561347 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BeOne Medicines | 76 |
| Massachusetts General Hospital | 758 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Colorado Blood Cancer Institute (CBCI) | Denver | United States | 2 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| University of Texas Southwestern Medical Center | Dallas | United States | 249 |